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POINT OF VIEW
Bioengineering horizon scan
2020
Abstract Horizon scanning is intended to identify the opportunities and threats associated with
technological, regulatory and social change. In 2017 some of the present authors conducted a horizon
scan for bioengineering (Wintle et al., 2017). Here we report the results of a new horizon scan that is
based on inputs from a larger and more international group of 38 participants. The final list of 20
issues includes topics spanning from the political (the regulation of genomic data, increased
philanthropic funding and malicious uses of neurochemicals) to the environmental (crops for changing
climates and agricultural gene drives). The early identification of such issues is relevant to researchers,
policy-makers and the wider public.
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Introduction
Bioengineering is expected to have profound
impacts on society in the near future as applica-
tions increase across multiple areas, while costs
and barriers to access fall. The speed of this
change and the breadth of the applications
make the task of forecasting the impacts of bio-
engineering both urgent and difficult (Gus-
ton, 2014). In 2017 we published the results of a
’horizon scan’ that looked at emerging issues in
bioengineering (Wintle et al., 2017). Here we
report the results of an updated horizon scan
based on a wider range of inputs (38 partici-
pants from six continents and 13 countries, com-
pared with 27 participants from the UK and US
in the 2017 exercise) and a broader definition of
bioengineering.
We followed the same structured ‘investigate,
discuss, estimate and aggregate’ (IDEA) proto-
col for identifying and prioritising issues
(Hanea et al., 2017), with some minor adjust-
ments (see Methods). We tasked our experts
with identifying ‘novel, plausible and high-
impact’ issues in biological engineering, and
they produced a long list of 83 issues. Partici-
pants then scored the issues anonymously (with
a score out of 1,000, reflecting likelihood,
impact and novelty), arriving at a short list of 41
issues to be discussed at a workshop. This was
coupled with a ‘yes/no’ question to determine
whether the issues were novel, based on
whether the experts had heard of the issue pre-
viously. After deliberation, participants re-scored
these issues. The issues identified in the latest
horizon scan differ substantially from those iden-
tified in 2017. This change likely stems from an
increase in the diversity of the participants,
improvements in the methods used, a broader
definition of bioengineering, and changes in the
research landscape since 2017.
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Since it was undertaken, there have been
developments in a number of the issues identi-
fied in the 2017 bioengineering horizon scan.
Human germline genome editing came to prom-
inence in late 2019 when researcher He Jiankui
announced the birth of two girls with CRISPR/
Cas9-edited genomes (Cyranoski, 2019). Mili-
tary funding of bioengineering projects also
remained substantial: for example, projects
funded by DARPA included programs to explore
the use bioelectronics for tissue repair and
regeneration (BETR) and to develop mosquito-
repellent skin (ReVector). There have also been
breakthroughs in the use of enhanced photosyn-
thesis for agricultural productivity: a 2018 study
reported that metabolic engineering strategies
increased photosynthetic efficiency by 17%,
which resulted in an increase of about 20% in
biomass in field conditions (South et al., 2019).
This technology is now being deployed in sev-
eral crops. The use of ‘platform technologies to
address emerging disease pandemics’, another
topic identified in 2017, has taken on particular
significance as a result of the COVID-19 pan-
demic. Many of the vaccine candidates for
COVID-19 currently undergoing clinical and pre-
clinical evaluation have been developed from
platforms for non-coronavirus candidates such as
influenza, SARs and Ebola (WHO, 2020).
Horizon scanning aims to build societal pre-
paredness by systematically identifying upcom-
ing opportunities and threats from
technological, regulatory and social change
(Sutherland and Woodroof, 2009). Horizon
scanning with the Delphi technique has a long
history. It has been used to identify emerging
critical issues in areas as diverse as conservation
biology (Sutherland et al., 2006;
Sutherland et al., 2017), invasive species in the
UK (Ricciardi et al., 2017), poverty reduction
(Pretty et al., 2010) and biosecurity
(Boddie et al., 2015). Periodic horizon scanning
is also undertaken in some areas: in global con-
servation, for example, these scans have identi-
fied issues such as micro-plastics, gene editing
for invasive species, and cultivated meat approx-
imately six years before they captured public
attention (Sutherland et al., 2017). Horizon-
scanning activities related to the Antarctic and
Southern Ocean (Kennicutt et al., 2014) have
also directed funding and policy
(Kennicutt et al., 2019), and helped to provide
the basis for research roadmaps
(Kennicutt et al., 2015).
In this article we provide a high-level sum-
mary of the top 20 issues identified in the bioen-
gineering horizon scan 2020 (while
acknowledging that the number of topics cov-
ered means that there will be some sacrifice of
depth for breadth). We take a broader view of
bioengineering than we did in 2017, defining it
as the application of ideas, principles and techni-
ques to the engineering of biological systems.
This means that we now cover more aspects of
bioengineering, as well as issues that contribute
to or result from bioengineering advances (such
as funding). To avoid giving a false sense of fore-
casting precision or overemphasising minor dif-
ferences in scoring, the issues are not ranked,
and are instead grouped into issues that are
expected to be most relevant within five years,
within 5–10 years, and on timescales of longer
than 10 years (Table 1). Our intent is to spur fur-
ther research into these issues and further dis-
cussion of their implications by researchers,
policy-makers and the wider public.
The issues most relevant within
five years
Access to biotechnology through
outsourcing
Traditionally, the biotechnology sector has had
high barriers to entry, with organizations need-
ing to build extensive physical and knowledge-
based assets. New ’cloud labs’ and services labs
are circumventing this model by using technolo-
gies such as robotics, automation and the inter-
net to offer widely-accessible standardised
services with limited need for physical material
transfer (Jessop-Fabre and Sonnenschein,
2019). This facilitates both broader access and
faster development of new products through the
sharing of capital and knowledge across projects
(Lentzos and Invernizzi, 2019). It is also helping
to empower non-traditional researchers by low-
ering the threshold for participating in cutting-
edge research.
This distributed approach poses a biosecurity
gap as research activities are separated from
intent: the cloud lab may not seek additional
details on an experiment’s context, including
why it is being performed. There is also a lack of
appropriate biosecurity guidelines and gover-
nance models to handle this (Palmer et al.,
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2015; Dunlap and Pauwels, 2019). As outsourc-
ing through cloud labs becomes increasingly
prevalent in the next five years, these challenges
may require the development of new guidelines
and business and incentive models for responsi-
ble innovation and biosecurity.
Crops for changing climates
Climate change is predicted to result in more
frequent droughts and intensive precipitation
events. This will increase soil salinity, elevate
average temperatures, and shift the range,
abundance and genotypic diversity of pollina-
tors, pests and pathogens. All of these factors
are expected to impact crop yields. In response,
efforts are intensifying to adapt food production
using agro-ecological strategies (Altieri et al.,
2015), as well as the provision of well-adapted
crop varieties by genetic engineering and new
breeding technologies (Dhankher and Foyer,
2018): Drought-tolerant genetically modified
(GM) plant varieties have reached the market
and more are in development (Nuccio et al.,
2018); the capabilities of plant immune recep-
tors have been broadened by protein engineer-
ing (De la Concepcion et al., 2019); and the
identification of conserved submergence-acti-
vated genes has revealed novel genetic targets
for enhancing flood tolerance (Reynoso et al.,
2019). Technical progress is still required for
success in the field. However, deployment may
be hindered by a comparative lack of funding
for plant science, as well as lengthy and expen-
sive regulatory regimes in most jurisdictions.
New models for public-private co-operation will
be needed to advance the translation of basic
research through to the field, including business
models that are not based on simple economic
returns. The effects of novel traits on biodiversity
and ecosystems will require further scrutiny
before being deployed in a warmer world.
Function-based design in protein
engineering
Despite a growing understanding of the relation-
ship between protein structure and function,
efficient design of new proteins with a desired
action has remained a laborious process. For
example, chimeric antigen receptor (CAR) thy-
mus lymphocyte (T cell) therapies which combine
functional protein moieties to activate T cells
against malignant tumours have only recently
been approved for human use after decades of
iteration (Feins et al., 2019). The convergence
of ongoing developments, including substantial
improvements in predicting protein structure
from amino acid sequences using machine learn-
ing (AlQuraishi, 2019; Yang et al., 2019a),
Table 1. Overview of the bioengineering horizon scan 2020.
Summary of the 20 issues identified through the scan; issues are grouped according to likely timeline for realisation.
<5 Years 5–10 Years >10 Years
Access to biotechnology through
outsourcing
Agricultural gene drives Bio-based production of materials
Crops for changing climates Neuronal probes
expanding new sensory
capabilities
Live plant dispensers of chemical
signals
Function-based design in protein
engineering
Distributed pharmaceutical
development and
manufacturing
Malicious use of advanced
neurochemistry
Philanthropy shapes bioscience
research agendas
Genetically engineered
phage therapy
Enhancing carbon sequestration
State and international regulation
of DNA database use
Human genomics
converging with
computing technologies
Porcine bioengineered
replacement organs
Microbiome engineering in
agriculture
The governance of cognitive
enhancement
Phytoremediation of
contaminated soils
Production of edible
vaccines in plants
The rise of personalised
medicine such as cell
therapies
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could overcome previous technical and compu-
tational challenges. This indicates a potential
revolution in function-based protein design,
leading to various useful industrial compounds
(such as the development of catalysts for any
desired organic reaction) and medical applica-
tions (such as the ability to selectively destroy,
suppress or stimulate any malfunctioning tissue,
which is the key to treating many refractory dis-
eases). However, as this field grows so will the
risk of deliberate misuse. Protein engineering
could be used to produce agents that have a
higher lethality or specificity than existing agents
(including new agents based on novel mecha-
nisms of action). Protein engineering might also
simplify the production of toxins currently
derived from natural sources.
Philanthropy shapes bioscience research
agendas
Over the past decade, philanthropic funding
(including venture philanthropy) of research and
innovation has been increasing (Coutts, 2019;
Depecker et al., 2018). This has largely been
driven by the increasing concentration of wealth,
and erosion of public health and scientific
research initiatives within key countries. These
investments can provide particular research
groups or areas with substantial funding over
prolonged periods of time, and they can also
support areas of research that are not usually
funded by governments. Philanthropic invest-
ments can also promote innovation, such as
allowing for more exotic approaches not usually
funded by governments. However, these invest-
ments might also influence the development of
biotechnologies in a way that has less of a public
mandate than government-funded research.
Philanthropic investments also operate without
the traditional mechanisms for accountability,
transparency or oversight often required by fed-
eral or state law (Reich, 2018). Some areas of
medical research are already considerably
underfunded compared to health needs
(Rafols and Yegros, 2018), and philanthropic
investments may exacerbate this discrepancy in
the near-term future. Significant investment into
a small range of actors could also undermine
diversity, particularly at the international level
(Lentzos, 2019). A possible response would be
partnerships between public and private invest-
ors, though such partnerships might not fully
address concerns about accountability, transpar-
ency or oversight.
State and international regulation of
deoxyribonucleic acid (DNA) database use
Personal genomic sequencing continues to drop
in price and increase in accessibility. The inher-
ent inability to truly anonymise such data, cou-
pled with the wealth of information it provides
on both individuals and families, distinguishes it
from conventional data types such as finger-
prints (identifiable but uninformative) or shop-
ping habits (Finnegan and Hall, 2017). The
drop in price and the use of technologies such
as cloud storage have allowed wider use of DNA
databases by different actors. While the vulnera-
bility of cloud infrastructure is a concern, there is
greater potential for misuse by states and law
enforcement in the name of security. This has
been seen in efforts to target Muslim Uighurs in
China via blood samples (Wee, 2019), and in a
consumer genetics database allowing the Fed-
eral Bureau of Investigation in the US to com-
pare genetic data from crime scenes to a
database of over two million profiles without
customer consent (Haag, 2019). The potential
to accrue and analyse vast amounts of genomic
information raises concerns over privacy, espe-
cially mass surveillance (Solove, 2011); the
potential expansion of state surveillance powers
necessitates dialogue and policy intervention
domestically and internationally.
Issues most relevant in 5–10 years
Agricultural gene drives
Gene drives were initially proposed for the con-
trol of insect vectors for human diseases
(Gantz et al., 2015; Neve, 2018), but recent
work suggest that they could provide major eco-
nomic benefits to the agricultural sector (Col-
lins, 2018; Neve, 2018). However, while there is
potential for gene drives to eliminate or sup-
press pest species, their widespread uptake and
use could lead to problems in their application
and governance (Evans and Palmer, 2018). One
concern is that commercial interests will seek to
maintain sales of agrochemicals by configuring
gene drives to reduce chemical resistance in tar-
get pest insects and weeds as opposed to caus-
ing sterility in those species. A second concern is
that unilateral deployment of gene drives may
cause rapid and unintended ecosystem pertur-
bations without proper oversight or recall. There
have also been questions around their control
and the lack of public consultation (or participa-
tion) regarding their release, as well as legal
implications if populations are eliminated within,
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or new gene configurations are carried to, native
locations (Montenegro de Wit, 2019). Efforts
are already underway to counter, control and
even reverse the undesired effects of genome
editing, including DARPA’s Safe Genes program
(Wegrzyn, 2019). Policy-makers will need to be
vigilant to more problematic applications as
agricultural gene drives become more prevalent.
Neuronal probes expanding new sensory
capabilities
New research into creating probes that mimic
neurons could enable novel medicinal and
enhancement applications such as the creation
of new sensory capabilities. Traditionally, neuro-
nal probes have both structural and mechanical
dissimilarities from their neuron targets, leading
to neuro-inflammatory responses. However, it is
now possible to fabricate neuron-like electronic
probes (with widths similar to those of neurons)
and unobtrusively fuse them with live neurons
(Yang et al., 2019b). Potentially, the technology
could be used to add new sensory capabilities
by implanting neuronal probe arrays as a visual
cortical prosthesis system. However, such biomi-
metic sensory probes could introduce unin-
tended vulnerabilities, from a risk of malicious
attack via the internet to possible mass monitor-
ing of implanted civilians by law enforcement
(Yetisen, 2018).
Distributed pharmaceutical development
andmanufacturing
Outsourcing and increasingly lower barriers to
access in bioengineering are allowing for greater
localisation and geographical distribution of the
manufacturing and development of pharmaceut-
icals. Bioengineering offers the capacity to cre-
ate pharmaceutical compounds or their
precursors by genetically modifying organisms
to produce them. The prospect of non-tradi-
tional pharmaceutical manufacture has gained
some traction, but with few tangible results. Bar-
riers to distributed pharmaceutical manufactur-
ing becoming broadly adopted include the scale
of production required for individual or commu-
nity use; meeting appropriate safety standards
for manufacturing and administration; and inter-
facing with drug approval pathways. Efforts in
non-traditional pharma, such as The Open Insulin
Project (Gallegos et al., 2018), are rising in pro-
file and will likely continue, whether individual
projects are successful or not. This is supported
by the Open Pharma movement which seeks to
empower innovation through open-access
research and development (Munos, 2010;
Gassmann et al., 2018; Open Source Pharma,
2020). That itself may shape regulatory frame-
works, and may provide new open or distributed
models for drug manufacturing. However, in the
absence of appropriate norms or regulations
(Blum, 2010), it may also lead to the
manufacturing, at scale, of drugs that are not
vetted for safety, or administered under appro-
priate clinical guidance (Coleman and Zilinskas,
2010).
Genetically engineered phage therapy
The World Health Organization (WHO) recently
reported a worrying lack of new antibiotics to
address the dangerous trends of rising resis-
tance to existing antibiotics (WHO, 2015), and
antimicrobial resistance has been identified as a
potential global catastrophic risk. Phage therapy
has recently seen a renaissance as a potential
alternative to antibiotic treatment. In particular,
the ability to rapidly engineer phage sequences
and phage cocktails opens up the prospect of
personalised treatments for tackling genetically-
diverse infections and overcoming problems of
antimicrobial resistance (Schmidt, 2019). The
technical advances observed in the medical
application of phage therapy will also have an
impact on other uses of phages as delivery sys-
tems in biotechnology. Efforts have also been
significantly buoyed by the development of eas-
ier methods for engineering phages to combat
the inevitable evolution of phage resistance in
bacteria (Pires et al., 2016). However, barriers
to widespread commercial use persist, including
high costs, instability of the medication, the
need to type the infection (instead of giving a
broad-spectrum pill) and immunogenicity. This
makes it more likely for phage therapy to be
used as a last resort once other treatments have
failed.
Human genomics converging with
computing technologies
Human genomics is increasingly incorporating
technologies such as blockchain, cloud comput-
ing and machine learning. Firms such as Amazon
and Google offer cloud computing-based stor-
age and data analytics services for the petabytes
of genetic data stored online, while companies
such as Encrypgen and Nebula use blockchain in
systems that reward individuals for sharing their
genetic data. Artificial intelligence and machine
learning are enabling deep analysis of thousands
of molecules with potential to become future
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drugs (Japsen, 2016), as well as human genomic
data (iCarbonX, 2018). Most recently, deep
learning used molecular structure to predict the
efficacy of antibiotic candidates (Stokes et al.,
2020). Some uses of these technologies could
help address current privacy concerns. This
includes the use of blockchain as well as ’secret
sharing’ techniques in which sensitive informa-
tion is divided across multiple servers
(Cho et al., 2018). However, as they are applied
to human genomic data in increasingly powerful
and connected ways, additional ethical issues
will arise. Enlivened and global discussion on
how best to handle societal implications will
become necessary (Yakubu et al., 2018).
Microbiome engineering in agriculture
Progress on microbiome engineering and geno-
mic sequencing could allow for beneficial new
applications in agriculture, but also risks. Micro-
biome engineering and the development of syn-
thetic microbiomes offer wide-ranging uses for
mammalian health as well as plant and animal
productivity, soil health and disease manage-
ment. A bottom-up approach to microbiome
engineering aims to predictably alter micro-
biome properties and design functions for agri-
cultural and therapeutic applications.
Microbiome engineering strategies could pro-
vide alternatives to the use of antibiotics for live-
stock management (Broaders et al., 2013).
These approaches offer the potential for innova-
tive, sustainable pathways for plant disease sup-
pression by engineering the microbiomes
indigenous to agricultural soils (Foo et al.,
2017). Advances in genome sequencing, meta-
genomics and synthetic biology have already
provided a theoretical framework for construct-
ing synthetic microbiomes with novel functionali-
ties. New methods, such as in situ mammalian
gut microbiome engineering, could help to over-
come existing limitations and offer new capabili-
ties for the future (Ronda et al., 2019). These
new methods and advances can support better
design of microbiome modulation strategies in
mammalian health and agricultural productivity.
Yet, the engineering of agricultural microbiomes
on a large scale could also create vulnerabilities
towards malicious intervention.
Phytoremediation of contaminated soils
Research in phytoremediation is leading to the
creation of engineered plants that could help
recuperate contaminated soils, but further field
trials are needed along with discussions about
their introduction to and implications for the
environment. Certain plant species have natural
mechanisms that enable both uptake and toler-
ance of natural and anthropogenic inorganic pol-
lutants. Identifying, expressing and potentially
engineering these traits is receiving increased
research interest. Preliminary work on transgenic
plants in the lab by overexpression of metal
ligands, transporters and specific enzymes has
led to successful phytoextractions of pollutants
including explosives and heavy metals. However,
few experiments have been conducted in the
field on contaminated soils (Fasani et al., 2018),
where toxicity of various pollutants and the
impact of various environmental factors on the
plant-microbiome interaction has limited the
success of phytoremediation to date. Realising
biotechnological phytoremediation will depend
on a number of factors: a more robust systemic
understanding of plant-microbiome interactions
with pollutants (Basu et al., 2018); the surviv-
ability of these engineered organisms in the
environment; understanding and controlling
environmental impacts; and robust societal dis-
cussion and carefully designed regulatory
regimes.
Production of edible vaccines in plants
Plants offer a scalable low-cost platform for
recombinant vaccine production (Merlin et al.,
2017). The introduction of the oral polio vaccine
in the 1960s led to huge interest in developing
vaccines that can be delivered without the need
for injection. Given that plants are widely con-
sumed, they offer an attractive means of vaccine
delivery. Plant-expressed antibodies can protect
against tooth decay. Similarly, expression of nor-
ovirus-like particles in transgenic potatoes could
raise antibodies against the virus when the mate-
rial is consumed (Tacket et al., 2000). Plant-pro-
duced vaccines have also been developed for
some animal diseases (Marsian et al., 2019).
Oral delivery with minimal processing has the
potential to reduce requirements for extensive
frameworks for production, purification, sterilisa-
tion, packaging and distribution. A major chal-
lenge is the need for improvement of the
chemical and physical stability of vaccines during
transit through the gut in order to ensure effi-
cacy (Berardi et al., 2018). Also, commercialisa-
tion may be difficult under current regulatory
regimes (Merlin et al., 2017). Moreover, if pro-
duction is scaled up beyond contained green-
houses, this will require the deliberate
environmental (field) release of plants engi-
neered to contain vaccines.
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The rise of personalised medicine such as
cell therapies
There is an accelerating trend towards the devel-
opment and approval of personalised therapeu-
tics. These are medical treatments that are
tailored towards individuals, accounting for their
likely response based on genomic and epige-
netic data. In the US in 2018, 42% of all new
drug approvals by the Food and Drugs Adminis-
tration concerned these treatments
(PMC, 2019). However, significant challenges
stand in the way of developing and deploying
personalised medicine and cell therapies. These
includes issues of delivery logistics and cost. The
key factor to clinical adoption of personalised
medicine is the value recognition by all health-
care stakeholders. Most personalised medicines
are genetically guided interventions that address
relatively small subsets of patients with rare
genetic mutations. The treatment approaches
are sometimes costlier due to their increased
sophistication and lower demand. Once these
barriers are overcome there will be some poten-
tial problems that will need to be mitigated via
policy. One is ensuring equitable access. Reim-
bursement from third-party payers such as
health insurance companies is also likely to
become an issue for targeted treatments
(Bilkey et al., 2019; Genetics Home Reference,
2019). Public health policy must adapt to this
new frontier of healthcare while addressing its
potentially detrimental effects on equality of
healthcare access and treatment.
The issues most relevant in 10
years or more
Bio-based production of materials
Biological engineering and production methods
facilitate the transformation of renewable plant
feedstocks and microorganisms into substitutes
for a wide range of existing and new materials,
including plastics and other materials that are
produced from fossil fuels
(European Commission, 2017). These develop-
ments are being driven by increasing govern-
ment, private and civil society efforts to
decarbonise economies. New opportunities may
be created for small, bio-based production facili-
ties and clean bio-refineries to be located close
to the markets for these materials, potentially
replacing much of the petrochemical sector, and
there are potential roles for rural areas in grow-
ing bio-based feedstocks. While bio-based pro-
duction promises to be more sustainable than
existing methods, attention is still required in
addressing specific impacts on feedstocks,
energy, water and other environmental and soci-
etal factors (Matthews et al., 2019). This is
accompanied by technical barriers in product
processing. While some bio-based materials are
already on the market, significant private invest-
ment and supportive public policy frameworks
(including but not limited to carbon pricing, as
well as more speculative nitrogen pricing) will be
required over the next decade and beyond to
accelerate the widespread worldwide transition
to these materials (HM Government, 2018).
Live plant dispensers of chemical signals
Plants emit volatile signals that can activate
defence responses in other nearby plants. The
concept of using GM plants to deliver these sig-
nals has made practical progress in recent years.
These genetically modified plants are intended
to be helpers that protect surrounding conven-
tional crops that are cultivated for consumption.
Field trials have evaluated the potential of trans-
genic wheat to repel different pests and virus
vectors (Bruce et al., 2015). Despite excellent
results in the lab, in planta synthesis of the alarm
pheromone failed to reduce aphid numbers.
Other studies have demonstrated the feasibility
of making insect sex pheromones to trap male
insects (Ding et al., 2014). Further finessing of
the pheromone blend may be enabled by syn-
thetic biology. This could open up the possibility
of using plants as chemical-producing green fac-
tories, or field-based disruptors and dispersers
of insect pests. Unlike current GM solutions for
protection from insect herbivory, the use of
pheromones is a non-lethal and less-persistent
intervention, and chemically-manufactured pher-
omones have been in use for many years. Ques-
tions remain as to whether the broader adoption
of pheromones will simply displace pests to
unprotected crops.
Malicious use of advanced neurochemistry
Agents that could attack the central nervous sys-
tem were investigated during the Cold War but
lack of knowledge only permitted the develop-
ment of sedating agents. Concerns over such
agents and manipulations continues
(Ward, 2019), but could be empowered through
advances in neuroscience and other fields. A
driving force in these advances is significant gov-
ernment interest and investments, including an
investment of almost $1bn by the US govern-
ment in the Brain Initiative (NIH, 2019).
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Resulting drugs and nootropics offer health ben-
efits, but could also be maliciously used
(Nixdorff et al., 2018). Governments could use
neuro-chemicals to make a populace more sub-
servient. Advanced applications in undeclared
biological warfare could include fostering emo-
tional resentment in a targeted population.
These drugs could be appealing to governments
around the world as a tool for counter-insur-
gency or non-lethal law enforcement. The use of
these new chemicals for law enforcement and in
non-traditional conflicts may greatly erode the
norms against chemical agent use on the battle-
field, threatening the Chemical Weapons Con-
vention in the long term.
Enhancing carbon sequestration
Metabolic engineering manipulates cells to pro-
duce target molecules by optimising endoge-
nous metabolic pathways or by reconstructing
these pathways in alternative species. ’Next
level’ metabolic engineering aims to design met-
abolic networks de novo, thus bypassing the
bottlenecks and inefficiencies of evolution
(Erb, 2019). Thus far, experimental success is
lacking. However, recent research in photosyn-
thesis may be promising, and examples include
engineering a new molecule to perform a
designed synthetic photorespiration bypass
(Trudeau et al., 2018) and developing an opti-
mised carbon dioxide fixation pathway using
enzymes from bacteria, archaea, plants and
humans (Schwander et al., 2016). Other meth-
ods have included laboratory evolution of a bac-
terium able to use CO2 for growth
(Gleizer et al., 2019). These approaches hold
potential for more efficient carbon sequestration
and biomass production, as well as for advanc-
ing the development of photovoltaics (the pro-
duction of electricity from light) and light-
sustained biomanufacturing. Yet, such develop-
ments remain speculative. There are still signifi-
cant technical challenges to overcome, and a
long path to widespread commercial deploy-
ment. Moreover, the field will need to engage
with its socio-political, ethical and environmental
dimensions.
Porcine bioengineered replacement organs
Pigs represent a promising candidate species for
production of human-compatible replacement
organs for xenotransplantation. A recent
advance in porcine genome editing using
CRISPR/Cas9 addresses one of the key scientific
challenges: successful inactivation of porcine
endogenous retroviruses, which otherwise pose
a risk of cross-species transmission (Niu et al.,
2017). Such advances hold promise as one tech-
nological way to address the global shortage of
transplant organs. Over 6,500 patients died
while on waiting lists in the USA alone in 2017
(UNOS, 2019). Several challenges remain,
including engineering sufficient immune compat-
ibility in the organs for successful human trans-
plantation, and determining the expected
lifespan of the porcine organs in humans. There
are differing views over the acceptability of por-
cine xenotransplantation within major religions,
such as Islam and Judaism (Nuffield Council on
Bioethics, 1996). Before commercial develop-
ment, consideration must be given to questions
surrounding the ethics of using animals for trans-
plantation, cost and access, and using a techni-
cal solution for an essentially social problem that
could be addressed through other approaches,
such as opt-out organ donation schemes.
The governance of cognitive enhancement
Cognitive enhancement is already a widely
embraced idea throughout society – caffeine is
the most widely consumed drug on earth. Novel
methods of cognitive enhancement such as noo-
tropics, wakefulness enhancers, or the potential
to directly modulate brain function through
implants or biotechnology are emerging. Uptake
of these is being driven by both a productivity-
focused culture, commercial opportunities and
increased understanding of neurochemistry.
Although some cognitive enhancers require pre-
scriptions, others only have to meet basic safety
guidelines and are available to purchase online.
While numerous trials have supported the safety
of most nootropics and wakefulness enhancers,
there are few long-term longitudinal studies
(Fond et al., 2015). A large section of those
who have embraced cognitive enhancement –
the ’do-it-yourself’ experimenters – may also be
ignored by the research community. Lax regula-
tion around safety standards for these products
and tools has led to calls to tighten regulatory
loopholes, and for academic researchers to part-
ner with and include communities in research on
cognitive enhancers (Wexler, 2017). Regulatory
frameworks are necessary to both minimise risks
and gather long-term safety data from end-
users, as well as to provide health and safety
guidance for international trade of cognitive
enhancing drugs and devices (Maslen et al.,
2015).
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Discussion
Emergent themes
Seven underlying themes emerged from the
workshop discussion: 1) political economy and
funding; 2) ethical and regulatory frameworks; 3)
climate change; 4) transitioning from lab to field;
5) inequalities; 6) technological convergence;
and 7) misuse of technology. None of these
were judged precise enough to qualify as hori-
zon-scanning items, although some sub-compo-
nents were. These themes represent underlying
commonalities and drivers across issues.
First, participants expressed concern about
the political economy of bioengineering (that is,
how political and economic institutions influence
bioengineering, including the role of regulation
and politics) and, related to this, about funding.
These concerns centred around a view that
research funded by the military, industry or phi-
lanthropy was less accountable than civilian gov-
ernment-funded research and could create real
or perceived conflicts of interest (see, for exam-
ple, Licurse et al., 2010).
Second, a recurring theme across several
issues was the need for ethics and better regula-
tory frameworks to manage the problems
expected to emerge from technologies on the
horizon. This was true for most issues
highlighted in the scan, ranging from carbon
sequestration to bioengineered replacement
organs. This underscores the need for greater
engagement between ethicists, social scientists,
policy-makers and the cutting-edge of
bioengineering.
Third, climate change is likely to be a critical
driver of bioengineering in the future. Our list
includes an application to both adaptation
(crops for changing climates) and negative emis-
sions (sequestration). Others, such as live plant
dispensers, could be boosted in relevance as a
way to enhance agricultural productivity in the
face of detrimental climate impacts. Progress in
climate policies will shape the development and
demand of bioengineering technologies. Cli-
mate change impacts will also create new prob-
lems that could be addressed through
bioengineering and policy. This includes changes
in the range of vector-borne diseases, such as
the expansion of tropical infectious diseases.
A fourth theme is that of transitioning from
lab to field. The deliberate release of a new bio-
engineering product into the environment
entails risks in both practice and perception.
Concerns over the unintended consequences of
environmental release have hindered the
deployment of GMOs and are now prominent in
discussions around gene drives (Evans et al.,
2019). Such concerns also factored into many of
the issues we have identified, most notably edi-
ble vaccines and live plant dispensers. Further
development of bioengineered products will
require appropriate regulation. Additionally, the
necessary social, environmental and human
health risk assessments need to take place to
transition bioengineering from the lab into the
wider world.
A fifth theme is the potential for bioengineer-
ing to exacerbate existing inequalities in wealth
and health. This factored into several issues
including the rise of personalised medicine,
replacement organs, and the regulation of cog-
nitive enhancement. In contrast, distributed
pharmaceutical development and manufacturing
was an emerging area fuelled in part by the
desire to deliver more equitable, cheap and
accessible medicine. Ensuring that the benefits
of bioengineering are spread fairly and widely
will be a defining feature of future debates.
Enhancements also come with risks, especially at
the earliest stages. Many of these are expected
to be borne by unwilling or uninformed recipi-
ents (as in the case of the CRISPR twins) before
being marketed to the wealthy. These problems
of inequality also highlight the need for horizon-
scanning efforts to make efforts to include rep-
resentatives from more oppressed and marginal-
ised groups.
The sixth theme is that the convergence of
different technologies will be crucial in the future
development of bioengineering. Many of the
issues in this horizon scan are driven by progress
in adjacent fields. Both neuronal probes and
malicious uses of neurochemistry will be enabled
by progress in neuroscience, and the overlap of
human genomics with computing technologies
brings both opportunities and threats. As auto-
mation and measurement, neuroscience, chemis-
try and artificial intelligence continue, they will
shape both what is possible and what is pursued
in bioengineering. This poses a challenge for
regulators, who may need to think about policy
that cuts across bioengineering into other areas,
such as cybersecurity. It also highlights a need
for continued horizon scanning and foresight
exercises to engage a broad range of technolog-
ical expertise so that key points of intersection
and convergence are not overlooked.
Last, our scan highlights ongoing concerns
around the misuse of technology by state or
non-state actors. Examples included various bio-
weapons and the misuse of DNA databases.
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The 2017 scan noted themes of equality, bio-
informatics and regulation, all of which feature
prominently in the 2020 scan (see Table 2 for a
summary of the previous scan). The 2017 exer-
cise discussed the intersection between biotech-
nology and information and digital technologies.
Technological convergence also features in the
present scan, but with a broader scope encom-
passing neuroscience (adding new sensory capa-
bilities) and neurochemistry (malicious uses of
advanced neurochemistry) as well as other fields.
Both scans featured a strong emphasis on the
potential for bioengineering to amplify or allevi-
ate inequalities. In the 2017 scan this included
the potential for human genomics to create new
’sociogenetic’ classes, while differences in
healthcare and access to cognitive enhancement
were the flagship issues in this 2020 scan. The
thematic convergence between the two scans
demonstrates that many of the underlying trends
in bioengineering include important structural
issues involving ethics and regulation. These will
likely influence the field for years to come. There
were also several differences in themes, includ-
ing the greater importance of climate change
and political economy in the 2020 exercise. This
reflects the significant deviation in issues
between the two studies.
Some issues from 2017 also appear in the
2020 exercise in a slightly altered form: concerns
about the military use of bioengineering are now
more specific (for example, ‘Malicious use of
advanced neurochemistry’), and there are new
concerns about the misuse of DNA databases.
Both scans also focussed on different meth-
ods for the production of replacement organs.
The 2017 exercise identified 3D printing cells on
organ-shaped scaffolds, while the 2020 exercise
examined the potential for porcine genome
editing to allow for xenotransplantation. Finally,
both scans assessed the issue of pharmaceutical
manufacturing becoming increasingly distrib-
uted. The 2017 exercise focused on start-up
entrepreneurs and biohacking communities,
whereas the 2020 exercise took a broader look
at the possibility of decentralisation.
The differences between the scans are likely
due to three reasons. First, we used a wider defi-
nition of bioengineering which encompassed
issues such as biomechanical implants. Two of
Table 2. Overview of the bioengineering horizon scan 2017.
Summary of the 20 issues identified in 2017; issues are grouped according to likely timeline for realisation.
<5Years 5–10 Years >10 Years
Artificial photosynthesis and
carbon capture for producing
biofuels
Regenerative medicine: 3D
printing body parts and
tissue engineering
New makers disrupt
pharmaceutical makers
Enhanced photosynthesis for
agricultural productivity
Microbiome-based
therapies
Platform technologies to address
emerging disease pandemics
New approaches to synthetic
gene drives
Producing vaccines and
human therapeutics in
plants
Challenges to Taxonomy-Based
description and management of
biological risk
Human genome editing Manufacturing illegal drugs
using engineered
organisms
Shifting ownership models in
biotechnology
Accelerating defense agency
research in biological engineering
Reassigning codons as
genetic firewalls
Securing the critical infrastructure
needed to deliver the
bioeconomy
Rise of automated tools for
biological design, test and
optimisation
Biology as information
science: impacts on global
governance
Intersection of information
security and bio-
automation
Effects of the Nagoya
Protocol on biological
engineering
Corporate espionage and
biocrime
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the issues identified in this scan would not have
been covered by the 2017 definition: neuronal
probes expanding new sensory capabilities and
the governance of cognitive enhancement. Sec-
ond, half of the participants (19/38) were not
involved in the 2017 scan; the new participants
were also more geographically diverse (see
Methods), and included a higher proportion of
social scientists. Third, there have been signifi-
cant changes in research and the world at large.
For example, all the research underpinning the
issue of neuronal probes has occurred in the last
three years. Similarly, recent research in climate
change has highlighted the continued increase
in emissions and warming (Friedlingstein et al.,
2019), and that tipping points are more proba-
ble than previously expected (Steffen et al.,
2018; Lenton et al., 2019).
Limitations and ways forward
While useful, horizon scanning has its limits. Cri-
tiques have suggested that the Delphi technique
(of which the IDEA protocol is a relatively recent
evolution) can give unjustified confidence in
results that are essentially the subjective judge-
ments of experts (Sackman, 1975). However, in
the absence of data, expert elicitation is war-
ranted, and structured approaches such as Del-
phi and the IDEA protocol have been found to
improve group judgement and outperform other
forecasting methods, such as prediction markets
(Hanea et al., 2017). While it is difficult to evalu-
ate the efficacy of the Delphi technique due to
inconsistencies in its application (de Loe¨ et al.,
2016), those that do exist are promising. A
review of a long-term Delphi in predicting devel-
opments in the health sector found that results
were accurate in 14/18 identified issues
(Parente and Anderson-Parente, 2011). The
method continues to show significant utility in
both accurately sighting emerging develop-
ments and exploring the implications of poten-
tial issues on the horizon.
We acknowledge that the issues identified in
this horizon scan are ultimately representative of
the participants involved. While the 2020 scan is
an improvement on previous efforts in terms of
diversity, the majority of respondents were still
from a developed economy background. The
scan did capture a large cross-section of aca-
demic sub-fields in bioengineering, but under-
represented industry, communities and policy-
makers. Moreover, we achieved a rough gender
balance with 21 male participants (55%) and 17
female participants (45%). We intend to make
the process increasingly global and diverse
under future triennial iterations, and by clearly
describing the methods used, have made the
process open for uptake by others.
Future pathways for forecasting bioengineer-
ing issues are manifold. Further updates of this
scan could be paired with systematic reviews of
their accuracy and efficacy, as well as deeper
dives into the issues that have been identified.
Extensions of the horizon-scanning process
could include: focusing on specific areas of bio-
engineering, such as catastrophic risks; incorpo-
rating decision-support tools such as fault-trees;
examining the development of bioengineering
issues in tandem with overlapping technological
areas such as artificial intelligence; and produc-
ing a policy-focused scan which involves greater
engagement with regulators.
Methods
Our study made use of the Investigate Discuss
Estimate Aggregate (IDEA) protocol. In this pro-
cess, participants were asked to investigate and
submit candidate issues, privately and anony-
mously score the gathered issues, and discuss
their thinking with others. They then provided a
second score which was mathematically aggre-
gated (Hanea et al., 2018a). The element of dis-
cussion is powerful, as the sharing of information
between participants has been shown to
improve the accuracy of Delphi-style forecasts
(Hanea et al., 2018b). The IDEA protocol has
also performed well relative to prediction mar-
kets in early studies (Hanea et al., 2017).
Despite being a relatively recent evolution of the
Delphi technique, the IDEA protocol has already
been successfully applied to a range of areas
including natural resource management
(Hemming et al., 2018) and assessing pollinator
abundance in response to environmental pres-
sures (Barons et al., 2018). Aside from seeking
a shared understanding of terms and reducing
linguistic ambiguity, consensus is not sought
during discussion and scores are kept anony-
mous during both rounds. This is done to avoid
undesirable group dynamics and peer pressure
distorting individual judgements. Our use of the
IDEA protocol can be split into three phases: i)
recruitment and issue gathering; ii) initial scor-
ing; and iii) workshop preparation, deliberation
and re-scoring.
Phase one: recruitment and issue gathering
Our study drew on a group of 38 participants
from six continents. Participants came from
countries including the UK, US, Canada,
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Australia, Germany, Croatia, Thailand, France,
Chile, Peru, Switzerland, Malaysia, Zambia and
Pakistan. Recruitment was done via a panel of
six initial experts (EP, PM, SO´hE´, CR-R, CR, LS
and BW). The panel aimed to ensure a balance
across areas such as plant sciences, medicine,
bioindustry and biosecurity. They also sought to
have a mix of approximately half new partici-
pants and half participants from the 2017 exer-
cise scan. Selected bioengineering scholars and
practitioners were asked to submit two to five
issues each. Our initial request was for issues
that were ‘novel, plausible and high-impact’. We
asked participants to provide issues that were at
a specific level of granularity. As with the previ-
ous scan we asked participants not to focus on a
general topic, such as ’gain of function’ research,
nor on multiple topics simultaneously. Instead
they were guided to focus on one area within a
general topic and its implications, such as an
emerging regulatory change for GMOs. After
duplicates were merged, a long list of 83 issues
was generated from the initial submissions. This
included 10 merged issues.
Phase two: scoring
Participants were asked to vote on the ’suitabil-
ity’ of these issues. This involved assigning a
score of 0–1,000 to each of the issues. Partici-
pants were asked to ensure that each score was
unique (no identical scores within a given score-
sheet). The suitability scores reflected a combi-
nation of plausibility, novelty and impact. Nov-
elty was also captured by respondents noting
whether they had heard of the issue previously
(through a ’yes/no’ response). We then calcu-
lated the percentage of participants who had
heard of each issue. These novelty scores were
published alongside all issues in the short list.
This was conducted by sending the participants
both the long list of issues, along with a tem-
plate score-sheet and instructions. At this stage
participants were reminded that "our aim is to
identify plausible, novel bioengineering-related
issues with important future implications for soci-
ety that are not too broad or already well
known’. They were given approximately three
weeks to complete their scoring. All anonymised
score-sheets are provided in Supplementary file
1; this file also includes the z-scores of the top
20 issues identified in the 2017 scan. Participants
were also able to provide comments on the dif-
ferent issues on the voting sheet. These critiques
led to a further eight issues being merged into
four. Comments were kept to stimulate future
discussion. We calculated the z-scores for each
participant’s issues scores. Z-scores are created
by subtracting the mean and dividing by the
standard deviation for each issue against the
participant’s set. This ensures that variations in
the range of participants’ scoring is accounted
for. We then ranked the average z-scores across
the issues and selected the highest ranked 41
(approximately cutting the long list in half).
We discussed two potential reforms on the
previous scoring approach: breaking scoring
down across the three criteria, and including
uncertainty estimates. We decided against both
potential reforms. Experts are poor at estimating
their own uncertainty and this could incentivise
overconfidence. We decided that greater disag-
gregation in voting was likely to impose a
greater burden on participants while providing
little additional benefit. Moreover, keeping the
protocol similar to the 2017 scan was desirable
for comparison.
One amendment was made to the previous
horizon-scanning methodology: the introduction
of ’devil’s advocates’ into the process.
Goodwin and Wright, 2010 have noted that
most forecasting methods are inadequate for
identifying high-impact, low-probability events
(some times called ’black swan events’). How-
ever, the Delphi technique can be better suited
to the task if it includes devil’s advocates who
can advocate for less likely but significant issues.
We empowered two individuals during the first
phase of the process to propose more specula-
tive and transformative issues. Two different par-
ticipants were then asked during the third phase
(workshop deliberation) to provide more critical
inputs and actively push against the prevailing,
dominant view during discussions. In each case
their designation was not revealed to the group.
The devil’s advocates appear to have been a
useful addition and were disproportionately suc-
cessful in suggesting issues. Six of the nine
issues they proposed in the first round made it
through to the short list, and four of the six
issues they proposed in the second round made
it through to the final list of 20; with 38 partici-
pants, we would expect approximately only one
issue for every second participant to make it
through to the final list. 68% of participants had
heard of the issues proposed by the devil’s
advocates, making these issues moderately
more novel than the rest. Overall, an average of
70% of participants had heard of each issue. The
level of novelty of the issues suggested by dev-
il’s advocates is partly skewed by two more well-
known issues which both scored 82.35%. When
both of these issues were excluded, the devil’s
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advocates suggestions were significantly more
novel at an average of 61%.
Phase three: workshop preparation,
deliberation and re-scoring
The 41 issues with the highest scores were kept
as a part of a shortlist. These were sent back to
participants on the 13th of September 2019.
Participants were assigned ’cynic’ roles for each
issue. This involved doing deeper background
research into the topic. Each issue had at least
two cynics, ensuring that at least three partici-
pants (the cynics and proposer) had an in-depth
knowledge of the area. The workshop was held
in Cambridge on the 9th of October 2019 with
25 participants; 13 could not attend due to other
obligations. This resulted in a group with
approximately the same characteristics as the
group that was involved in he first two phases.
The characteristics of both groups are compared
in Table 3. Overall, the gender balance was
maintained (although the slight skew was
reversed towards female participants), the disci-
plinary split between social and physical scien-
tists was approximately the same, and the
geographical coverage became less balanced
due to the loss of participants from Peru, Zambia
and Malaysia.
These discussions were overseen by an expe-
rienced facilitator (WJS, with LK and AR acting
as scribes) and followed a deliberate structure.
Each issue was discussed for approximately ten
minutes before being voted on anonymously.
During discussions, proposers of the issue were
asked not to speak until at least three other
respondents had contributed. This was done to
avoid biasing the conversation and allowing the
cynics time to provide an orientating, more neu-
tral intervention. The standardised z-scores for
each issue were calculated and ranked at the
end of the workshop, resulting in a top 20 list.
The decision to keep the list to 20 was made by
consensus by the workshop group and was influ-
enced by a significant difference between the
z-scores of the top and bottom 20 issues, but a
much smaller spread of scores within the top 20.
Participants were then given time to discuss the
final list and whether any amendments were
needed. The group was content with the spread
of the final list and that it accurately reflected
the deliberations and hence decided that no
alterations were needed.
A comparison of the rankings of the top 20
issues after the first and second round of scoring
can be found in Supplementary file 2. There
was a noticeable difference between the two
rankings. For example, 11 out of the final top 20
(55%) issues had been ranked outside of the top
20 during the first round of scoring. Indeed, four
of the top five issues (80%) were outside the top
20 after the first round of scoring. This suggests
that deliberation was effective in shifting partici-
pants’ perspectives and scores. The novelty
scores are also summarised in
Supplementary file 2. The final list of issues had
a slightly higher degree of novelty, but this was
minor. The short list of issues resulted in an aver-
age score of 70.52% and a median of 73.53%.
By contrast the final list had an average of
68.97% and a median of 67.75%.
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